IDH1 and astrocytoma (excluding glioblastoma): A Phase 1 trial of mesenchymal-derived stem cells loaded with DNX-2401 administered to patients with GBM, IDH-mutant astrocytoma grade 4, gliosarcoma, or wild-type IDH-1 anaplastic astrocytoma is currently ongoing (NCT03896568).